Saad R El-Zemity
Overview
Explore the profile of Saad R El-Zemity including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
13
Followers
0
Related Specialties
Related Specialties
Co-Authors
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Discovery of new thymol-3,4-disubstituted thiazole hybrids as dual COX-2/5-LOX inhibitors with proof
El-Miligy M, Al-Kubeisi A, Nassra R, El-Zemity S, Hazzaa A
J Enzyme Inhib Med Chem
. 2024 Jan;
39(1):2309171.
PMID: 38291670
New thymol-3,4-disubstitutedthiazole hybrids were synthesised as dual COX-2/5-LOX inhibitors. Compounds , , , and displayed inhibitory activity against COX-2 (IC= 0.037, 0.042, 0.046, and 0.039 µM nearly equal to celecoxib...
2.
El-Miligy M, Al-Kubeisi A, Bekhit M, El-Zemity S, Nassra R, Hazzaa A
J Enzyme Inhib Med Chem
. 2022 Nov;
38(1):294-308.
PMID: 36408833
New thymol - 1,5-disubstitutedpyrazole hybrids were synthesised as dual COX-2/5-LOX inhibitors. Compounds , , and displayed inhibitory activity against COX-2 (IC= 0.043, 0.045, 0.063, and 0.068 µM nearly equal to...
3.
El-Miligy M, Al-Kubeisi A, El-Zemity S, Nassra R, Abu-Serie M, Hazzaa A
Bioorg Chem
. 2021 Jul;
115:105171.
PMID: 34303896
Colorectal cancer (CRC) is the second cause of cancer death worldwide. Inhibitors of COX-2, 5-LOX and PIM-1 kinase were very effective in the treatment and prevention of CRC in mouse...